By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated - 2A NASA spacecraft orbiting Mars may be dead
- 3How Would You Like to Deal with Your Funds?
- 4Understanding climate change in America: Skepticism, dogmatism and personal experience
- 5China resumes flights to North Korea after a six-year pause
- What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Which Carrier Do You Suggest? Vote
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- An eye for an eye: People agree about the values of body parts across cultures and eras
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
